Effect of Probiotic Formula DE111® on Immune System in Preschool Children
NCT ID: NCT04077034
Last Updated: 2019-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
102 participants
INTERVENTIONAL
2019-04-02
2019-08-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bifidobacterium Animalis Subsp. Lactis in Prevention of Common Infections in Healthy Children Attending Day Care Centers
NCT01702753
A Study to Investigate the Effect of Probiotics (L. Reuteri ATCC PTA 5289 and L. Reuteri DSM 17938) on Symptoms of Viral Upper Respiratory Tract Infections in Children
NCT06205966
Influence of Probiotics on Prevention of Atopy, Atopic Disease and Immunological Responses
NCT00318695
Probiotics in Respiratory Tract Infections in Children
NCT01510938
Beneficial Effects of Lactobacillus Reuteri DSM 17938 Supplementation on Asthmatic Children
NCT01241084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental group
Probiotic DE111®
Probiotic Formula Bacillus subtilis DE111®
Probiotic Formula Bacillus subtilis DE111®, 1 billion colony forming units (CFU) per day for 8 weeks
Control group
Placebo
Placebo comparator
Placebo comparator, once a day for 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic Formula Bacillus subtilis DE111®
Probiotic Formula Bacillus subtilis DE111®, 1 billion colony forming units (CFU) per day for 8 weeks
Placebo comparator
Placebo comparator, once a day for 8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* children aged 2 to 6 years
* attending or about to start attending day-care
Exclusion Criteria
* gestational age \<37 weeks
* severe chronic illness
* regular use of medication
* immunodeficiency
* parent or legal guardian not able to understand and comply with requirements of the study
2 Years
6 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vizera d.o.o.
INDUSTRY
University of Ljubljana
OTHER
Deerland Enzymes
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lilijana Kocijancic Besednjak, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Health Center Nova Gorica
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Health center Laško
Laško, , Slovenia
Pediatrija Krebs
Maribor, , Slovenia
Pediatrinja d.o.o.
Maribor, , Slovenia
Zasebna otroska in solska ambulanta
Maribor, , Slovenia
Health Center Nova Gorica
Šempeter pri Gorici, , Slovenia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IMMUNO-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.